Frequently asked questions
The global nephrology drugs market was valued at USD 16248.5 Million in 2022.
The nephrology drugs market is expected to grow at a CAGR of 5.9% between 2023 and 2030, reaching USD 25702.8 Million in 2030.
Immunosuppressants are the leading segment by product, holding over 25% share in value in 2022.
The chronic kidney disease (CKD) segment governs the global demand for nephrology drugs, holding a massive market share of over 60% in 2022.
The specialized nephrology clinics segment will post the highest CAGR over the projection period.
North America is fueling the rapid growth of the nephrology drugs industry, with over one-third of its share in 2022.
The top players include AstraZeneca, Pfizer Inc, Amgen Inc, FibroGen Inc, GlaxoSmithKline Plc, AbbVie Inc, Akebia Therapeutics Inc, Teva Pharmaceutical Industries, Johnson & Johnson Inc, F. Hoffmann-La Roche, and Others.
The major market drivers are the rising prevalence of kidney diseases, particularly due to risk factors like diabetes and hypertension, and advancements in pharmaceutical research leading to innovative drug therapies.
The major market restraints are the high cost of nephrology drugs, limited awareness and delayed diagnosis of kidney diseases, and the emergence of drug-resistant strains of kidney-related pathogens.
The major market opportunities are the expansion of remote patient monitoring and telemedicine, advancements in precision medicine and regenerative therapies, and the growing emphasis on disease prevention and early intervention strategies.